Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

By | August 9, 2022
In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.